TY - JOUR
T1 - A childhood-onset intestinal toxemia botulism during chemotherapy for relapsed acute leukemia
AU - Ohyama, Noriko
AU - Torio, Michiko
AU - Nakashima, Kentaro
AU - Koga, Yuuki
AU - Kanno, Shunsuke
AU - Nishio, Hisanori
AU - Nishiyama, Kei
AU - Sasazuki, Momoko
AU - Kato, Haru
AU - Asakura, Hiroshi
AU - Akamine, Satoshi
AU - Sanefuji, Masafumi
AU - Ishizaki, Yoshito
AU - Sakai, Yasunari
AU - Ohga, Shouichi
N1 - Funding Information:
We thank Drs. Ryutaro Kira (Fukuoka Children's Hospital) and Toshio Hanai (Yanagawa Institute for Developmental Disabilities) for helpful discussions. This study is supported in part by JSPS Kakenhi grant number 15K09624 (YS), 16K09991 (MS), 17K16301(MT), Evidence-based Early Diagnosis and Treatment Strategies for Neuroimmunological Diseases from the Ministry of Health, Labour and Welfare of Japan (YS), and The Japan Epilepsy Research Foundation (YS).
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/9/18
Y1 - 2017/9/18
N2 - Background: Botulism is a potentially fatal infection characterized by progressive muscle weakness, bulbar paralysis, constipation and other autonomic dysfunctions. A recent report suggested that cancer chemotherapy might increase the risk for the intestinal toxemia botulism in both adults and children. Case presentation: We report a 5-year-old boy, who developed general muscle weakness, constipation, ptosis and mydriasis during the third induction therapy for relapsed acute myeloid leukemia. He had recent histories of multiple antibiotic therapy for bacteremia and intake of well water at home. Repeated bacterial cultures identified Clostridium botulinum producing botulinum neurotoxin A. Botulinum toxin A was isolated from his stools at 17, 21, and 23 days after the onset. Symptoms were self-limiting, and were fully recovered without anti-botulinum toxin globulin therapy. Conclusion: This is the second report of a pediatric case with cancer chemotherapy-associated intestinal toxemia botulism. Our case provides further evidence that the immunocompromised status due to anti-cancer treatments increases the risk for the development of botulism at all ages in childhood.
AB - Background: Botulism is a potentially fatal infection characterized by progressive muscle weakness, bulbar paralysis, constipation and other autonomic dysfunctions. A recent report suggested that cancer chemotherapy might increase the risk for the intestinal toxemia botulism in both adults and children. Case presentation: We report a 5-year-old boy, who developed general muscle weakness, constipation, ptosis and mydriasis during the third induction therapy for relapsed acute myeloid leukemia. He had recent histories of multiple antibiotic therapy for bacteremia and intake of well water at home. Repeated bacterial cultures identified Clostridium botulinum producing botulinum neurotoxin A. Botulinum toxin A was isolated from his stools at 17, 21, and 23 days after the onset. Symptoms were self-limiting, and were fully recovered without anti-botulinum toxin globulin therapy. Conclusion: This is the second report of a pediatric case with cancer chemotherapy-associated intestinal toxemia botulism. Our case provides further evidence that the immunocompromised status due to anti-cancer treatments increases the risk for the development of botulism at all ages in childhood.
UR - http://www.scopus.com/inward/record.url?scp=85029608022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029608022&partnerID=8YFLogxK
U2 - 10.1186/s12941-017-0240-y
DO - 10.1186/s12941-017-0240-y
M3 - Article
C2 - 28923072
AN - SCOPUS:85029608022
SN - 1476-0711
VL - 16
JO - Annals of Clinical Microbiology and Antimicrobials
JF - Annals of Clinical Microbiology and Antimicrobials
IS - 1
M1 - 61
ER -